Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Snijders, C. S. de Graaff, T. S. van der Werff, W. G. Boersma (Groningen, Netherlands). The influence of prednisolone on C-reactive protein and procalcitonin in patients hospitalised with community-acquired pneumonia. Eur Respir J 2010; 36: Suppl. 54, 3440

Member's Comments

No comment yet.

Related content which might interest you: Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 488s Year: 2006 Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia Source: Eur Respir J 2008; 32: 726-732 Year: 2008 C-reactive protein in community-acquired pneumonia Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients Source: Eur Respir J 2004; 24: Suppl. 48, 188s Year: 2004 Serum procalcitonin and community-acquired pneumonia in childhood Source: Eur Respir J 2005; 26: Suppl. 49, 167s Year: 2005 High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Measurements usefulness of serum C-reactive protein for management of adult community-acquired pneumonia Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia Source: Eur Respir J 2010; 35: 805-811 Year: 2010 Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Pro-adrenomedullin, procalcitonin and CRP levels to predict bacterial pneumonia in patients admitted to emergency room Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia Source: Eur Respir J 2005; 25: 688-692 Year: 2005 Procalcitonin versus C-reactive protein in the management of severe acute exacerbations of COPD Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD Year: 2010 Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013 Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP) Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 CRP and ESR as discharged criteria of patients admitted with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 374s Year: 2006 Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia Source: Eur Respir J 2008; 31: 356-362 Year: 2008 Calprotectin as a biomarker of pneumonia in patients hospitalized with AECOPD Source: International Congress 2019 – Airway infection in COPD Year: 2019 Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007